Bupropion and cognitive-behavioral treatment for depression in smoking cessation
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
This study is a randomized, double-blind, placebo-controlled clinical trial examining the effects of an intensive cognitive-behavioral mood management treatment (CBTD) and of bupropion, both singularly and in combination, on smoking cessation in adult smokers. As an extension of our previous work, we planned to examine the synergistic effects of CBTD and bupropion on smoking cessation outcomes in general and among smokers with depression vulnerability factors. Participants were 524 smokers (47.5% female, M (age) = 44.27 years) who were randomized to one of four 12-week treatments: (a) standard, cognitive-behavioral smoking cessation treatment (ST) plus bupropion (BUP), (b) ST plus placebo (PLAC), (c) standard cessation treatment combined with cognitive-behavioral treatment for depression (CBTD) plus BUP, and (d) CBTD plus PLAC. Follow-up assessments were conducted 2, 6, and 12 months after treatment, and self-reported abstinence was verified biochemically. Consistent with previous studies, bupropion, in comparison with placebo, resulted in better smoking outcomes in both intensive group treatments. Adding CBTD to standard intensive group treatment did not result in improved smoking cessation outcomes. In addition, neither CBTD nor bupropion, either alone or in combination, was differentially effective for smokers with single-past-episode major depressive disorder (MDD), recurrent MDD, or elevated depressive symptoms. However, findings with regard to recurrent MDD and elevated depressive symptoms should be interpreted with caution given the low rate of recurrent MDD and the low level of depressive symptoms in our sample. An a priori test of treatment effects in smokers with these depression vulnerability factors is warranted in future clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Biochemical verification of tobacco use and cessation
Benowitz, N. L., III, P. J., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J., Hansson, A., Lichtenstein, E., Henningfield, J., Tsoh, J., et al. (2002) · Nicotine & Tobacco Research · doi:10.1080/14622200210123581 · Cited by 1,800
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 2×
“Bupropion has consistently outperformed placebo in acute smoking cessation studies (Gonzales et al., 2001; Hall et al., 2002; Hurt et al., 1997; Jorenby et al., 1999; Simon, Duncan, Carmody, & Hudes, 2004; Tonnesen et al., 2003); in relapse prevention studies (Cox et al., 2004; Hays et al., 2001);…”
BackgroundMethodInfluentialKeller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331 · cited 1×
“Reviews (Conte, Plutchik, Wild, & Karasu, 1986; Friedman et al., 2004b) and studies (Keller et al., 2000; Miller et al., 2005) suggest that combined psychotherapy plus pharmacotherapy can be more effective than either treatment alone for MDD. Similarly, the clinical practice guideline for the…”
BackgroundSelf-citationGrant, B. F., Hasin, D. S., Chou, S. P., Stinson, F. S., & Dawson, D. A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1107 · Cited by 1,262
Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989 · cited 2×
“after looking to the depression treatment literature, which indicates that the typical course of cognitive– behavioral treatment for MDD is 16–20 sessions (DeRubeis et al., 2005; Hollon et al., 1992) and that”
BackgroundMethodCognitive Therapy and Pharmacotherapy for Depression: Singly and in Combination
Hollon, S. D. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100018004 · Cited by 481 · cited 1×
“…treatment literature, which indicates that the typical course of cognitive– behavioral treatment for MDD is 16–20 sessions (DeRubeis et al., 2005; Hollon et al., 1992) and that the benefits of combined psychotherapy and pharmacotherapy have been demonstrated (Friedman et al., 2004a; Hollon et…”
BackgroundNortriptyline and Cognitive-Behavioral Therapy in the Treatment of Cigarette Smoking
Hall, S. M., Reus, V. I., Muñoz, R. F., Sees, K. L., Humfleet, G., Hartz, D. T., Frederick, S., & Triffleman, E. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.683 · Cited by 385 · cited 3×
“session mood management treatment was compared with a 5-session control condition, smokers with past MDD had better smoking outcomes with the mood management condition (Hall et al., 1994; Hall et al., 1998).”
MethodHays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
Self-citationHistory of depression and smoking cessation outcome: A meta-analysis.
Hitsman, B., Borrelli, B., McChargue, D. E., Spring, B., & Niaura, R. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.4.657 · Cited by 253
Self-citationTonstad, S. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00003-4 · Cited by 246
Evins, A. E., Mays, V. K., Rigotti, N. A., Tisdale, T., Cather, C., & Goff, D. C. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110073920 · Cited by 191 · cited 2×
“…disease (Tonstad et al., 2003), those with post-traumatic stress disorder (Hertzberg, Moore, Feldman, & Beckham, 2001), those with schizophrenia (Evins et al., 2001; George et al., 2002), hospital employees (Dalsgaro et al., 2004), African Americans (Ahluwalia, Harris, Catley, Okuyemi, & Mayo,…”
BackgroundThe effects of depressed mood on smoking cessation: Mediation by postcessation self-efficacy.
Cinciripini, P. M., Wetter, D. W., Fouladi, R. T., Blalock, J. A., Carter, B. L., Cinciripini, L. G., & Baile, W. F. (2003) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.71.2.292 · Cited by 181 · cited 2×
“…(Covey, 2004; Hall, 2004; Hitsman, Borrelli, McChargue, Spring, & Niaura, 2003), depressive symptoms (Niaura et al., 2001) and negative moods (Cinciripini et al., 2003; Ginsberg, Hall, Reus, & Muñoz, 1995; Killen et al., 1996; Kinnunen, Doherty, Militello, & Garvey, 1996) have been…”
Gonzales, D. H., Nides, M. A., Ferry, L. H., Kustra, R. P., Jamerson, B. D., Segall, N., Herrero, L. A., Krishen, A., Sweeney, A., Buaron, K., et al. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115750 · Cited by 143
. Combined psychotherapy and pharmacotherapy for the treatment of major depressive disorder.
Friedman, M. A., Detweiler-Bedell, J. B., Leventhal, H. E., Horne, R., Keitner, G. I., & Miller, I. W. (2004) · Clinical Psychology: Science and Practice · doi:10.1093/clipsy.bph052 · Cited by 123 · cited 2×
“…literature, which indicates that the typical course of cognitive– behavioral treatment for MDD is 16–20 sessions (DeRubeis et al., 2005; Hollon et al., 1992) and that the benefits of combined psychotherapy and pharmacotherapy have been demonstrated (Friedman et al., 2004a; Hollon et al., 2005).”
BackgroundSelf-citationBupropion for Smoking Cessation: A Randomized Trial
Simon, J. A., Duncan, C., Carmody, T. P., & Hudes, E. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.16.1797 · Cited by 81
Depression and the Dynamics of Smoking: A National Perspective
Anda, R. F. (1990) · JAMA · doi:10.1001/jama.1990.03450120053028 · Cited by 28 · cited 1×
“The scale has demonstrated good reliability and validity (Radloff, 1977) and has been found to be associated significantly with current smoking status and inability to quit in the general population (Anda et al., 1990).”
Background
Cited by
Combined pharmacotherapy and behavioural interventions for smoking cessation
Stead, L. F., Koilpillai, P., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008286.pub3 · Cited by 829
Group behaviour therapy programmes for smoking cessation
Stead, L. F., Carroll, A. J., & Lancaster, T. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001007.pub3 · Cited by 781
Antidepressants for smoking cessation
Hughes, J. R., Stead, L. F., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000031.pub3 · Cited by 567
Leventhal, A. M., & Zvolensky, M. J. (2015) · Psychological Bulletin · doi:10.1037/bul0000003 · Cited by 524
“…quitting have generally yielded modest (e.g., Cinciripini et al., 1995; McFall et al., 2005, 2010; Piper et al., 2008) or mixed (e.g., R. A. Brown et al., 2007; Hitsman, Borrelli, McChargue, Spring, & Niaura, 2003; Hitsman et al., 2013) results on cessation outcomes and, in some cases,…”
Group behaviour therapy programmes for smoking cessation
Stead, L. F., & Lancaster, T. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001007.pub2 · Cited by 405
Metadata
- Authors
- Brown, R. A., Niaura, R., Lloyd-Richardson, E. E., Strong, D. R., Kahler, C. W., Abrantes, A. M., Abrams, D., & Miller, I. W.
- Venue
- Nicotine & Tobacco Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-07
- Volume
- 9
- Issue
- 7
- Pages
- 721-730
- ISSN
- 1462-2203 (ISSN-L)
- OpenAlex
- W2029138083
- Cited by
- 103
- References
- 17
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.